Riskpilot← Back to searchSign inGet full accessSveanova Pharma AB
ABActiveOrg 5590581749Strömkarlsgränd 16Retail sale of clothing · NACE 4771Est. 20160 employees
Revenue 2024
SEK 0
EBITDA margin
—
-163% vs 2023
Equity ratio
-18.6%
Financial strength
Net profit 2024
SEK -7K
-163% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -7K | -163% |
| Net profit | SEK -7K | -163% |
| Total assets | SEK 203K | +2136% |
| Equity | SEK -38K | -23% |
| Employees | 0 | — |
Legal name
Sveanova Pharma AB
Org number
5590581749
Legal form
Aktiebolag
NACE code
4771 · Retail sale of clothing
Founded
8 april 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva handel med läkemedel, medicinsk utrustning, hälsokost, kosmetik och hudvård med läkemedelsfunktion, därmed förenlig verksamhet.
Address
Strömkarlsgränd 16
Email
majinze2015@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −18 | −11 | −40 | −3 | −7 |
| Depreciation & amort. | −9 | −8 | −2 | — | — |
| EBIT | −27 | −19 | −42 | −3 | −7 |
| Net financials | — | — | 0 | — | — |
| Profit before tax | −27 | −19 | −42 | −3 | −7 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −27 | −19 | −42 | −3 | −7 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 23 | 14 | 11 | 9 | 203 |
| Equity | 23 | 14 | −28 | −31 | −38 |
| Long-term debt | 0 | 0 | — | — | 200 |
| Short-term debt | 0 | 0 | 40 | 40 | 41 |
| Total debt | — | — | 40 | 40 | 241 |
EBITDA margin
-702900.0%
This company
15.8%
Market median
-4448834% vs market
20202024
Equity ratio
-18.6%
This company
38.2%
Market median
-149% vs market
20202024
Return on equity
-702900.0%
This company
18.4%
Market median
-3820209% vs market
20202024
Net profit margin
-702900.0%
This company
8.1%
Market median
-8677878% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
6.38×
This company
0.62×
Market median
-929% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MZ Chief Executive Officer | Chief Executive Officer | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
JM | Board of Directors | 2022 |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sveanova Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mingshan Zhao | Chief Executive Officer | 0 companies |
| Xiaoting Sheng | Deputy Board Member | 0 companies |
| Jinze Ma | Board of Directors | 0 companies |